Search

Your search keyword '"Bittoni, Alessandro"' showing total 277 results

Search Constraints

Start Over You searched for: Author "Bittoni, Alessandro" Remove constraint Author: "Bittoni, Alessandro"
277 results on '"Bittoni, Alessandro"'

Search Results

1. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

2. Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic Colorectal Carcinoma: The Way Forward for Personalized Treatment? A Single-Center Experience.

3. The Role of Multigene Panel Next-Generation Sequencing Techniques in Managing Patients with Metastatic Colorectal Carcinoma

8. Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy

9. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.

10. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

14. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

17. Palliative Treatment

23. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

24. Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients

26. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial

28. An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer

29. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer

33. Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

34. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

35. Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia

36. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

37. Optimal management of resected gastric cancer

38. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival

39. Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy

40. Medical treatment for cholangiocarcinoma

43. Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

45. Size does matter: Comparison of activity between anti-EGFR and anti-VEGF based-treatments in RAS wild type colorectal cancer patients, stratified by sizes of metastatic involvement

46. Primary tumor site (pTS) as a key factor in influencing differential outcome in resected colorectal cancer patients treated with adjuvant XELOX/FOLFOX6

47. Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

48. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma

49. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

50. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy

Catalog

Books, media, physical & digital resources